Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
企業コードDYAI
会社名Dyadic International Inc
上場日Nov 05, 2004
最高経営責任者「CEO」Mr. Mark A. Emalfarb
従業員数6
証券種類Ordinary Share
決算期末Nov 05
本社所在地1044 North U.S. Highway One
都市JUPITER
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号33477
電話番号15617438333
ウェブサイトhttps://dyadic.com/
企業コードDYAI
上場日Nov 05, 2004
最高経営責任者「CEO」Mr. Mark A. Emalfarb
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし